Navigation Links
Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
Date:1/12/2009

HOPKINTON, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. today announced that on January 8, 2009, it received notice from the NASDAQ Stock Market ("NASDAQ") that for the last 10 consecutive trading days, the market value of its listed securities has been below the minimum $35 million requirement for continued inclusion under NASDAQ Marketplace 4310(c)(3)(B). Furthermore, NASDAQ stated that the Company does not comply with NASDAQ Marketplace Rule 4310(c)(3)(A) or 4310(c)(3)(C), which requires the Company to have either minimum stockholders' equity of $2.5 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

In accordance with NASDAQ Marketplace Rule 4310(c)(8)(C), the Company was provided thirty calendar days, or until February 9, 2009 (the "Compliance Period"), to regain compliance. This requires, at a minimum, that the market value of listed securities of the Company's common stock remain $35,000,000 or more for a minimum of 10 consecutive business days at anytime prior to February 9, 2009.

If the Company does not regain compliance within the Compliance Period, NASDAQ will provide the Company with written notification that the Company's common stock will be delisted from the NASDAQ Capital Market. At that time, the Company may appeal the determination by the NASDAQ Staff to delist its common stock to a Listing Qualifications Panel. The Company is currently considering actions that may allow it to regain compliance with the NASDAQ continued listing standards and maintain its NASDAQ listing. There is no assurance that the Company will be able to take any of these actions or that any of the actions will be sufficient to allow the Co
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
10. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
11. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... (PRWEB) July 26, 2014 ... recently updated by Vkool.com, this is a ... safe methods for treating all types of ...     Tinnitus due to Ménière's ... ,     Nerve pathway tinnitus , ...
(Date:7/26/2014)... The U.S. Food & Drug Administration (FDA) has released ... guide for AndroGel to include blood clots in the legs ... low testosterone medication, notes Wright & Schulte LLC. The ... low testosterone theapy drug, has also updated the official AndroGel ... signs of a blood clot in the leg and difficulty ...
(Date:7/26/2014)... 2014 According to the "Get Rid ... is a comprehensive guide that provides readers with safe ... This book also teaches them how to fade dark ... in their own home for drastic results. , ... Naturally" book includes step-by-step tutorials and product recommendations for ...
(Date:7/25/2014)... 2014 Deep Research Report ... Industry” is a professional and in-depth research ... Permeation Chromatography market. The report provides basic ... Chromatography definition, classification, application, and industry chain ... research covers the international market analysis, including ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... dismissal and summary judgment in two DePuy Pinnacle hip ... paving the way for the claims to go before ... reports. In an opinion rendered on July 18th, U.S. ... Texas, ruled that the two Plaintiffs’ claims may proceed ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... ... for their innovative solutions for reducing stress and improving health and well-being, is offering ... can be given as gifts. Their Beautiful Heart Award is expected to be very ... corner. , ...
... Feb. 4   When Mary Gill went to bed ... even Mary. She was thin and 42 years old. She exercised regularly, ... recipe for turning a young mom into a tragic statistic. , "Heart ... that night with an upset stomach, I wasn,t thinking heart attack." , ...
... , LACHEN, ... Octapharma USA will accept applications until ... , which supports clinical or pre-clinical research focused on human protein therapies ... reviewed in April. , Octapharma AG , one of the largest ...
... discovered unexpected properties for a precursor to melatonin, the ... from the neurotransmitter serotonin in a daily rhythm that ... previously thought to have effects separate from those of ... shown that N-acetylserotonin can stimulate the same circuits in ...
... National Heart, Lung, and Blood Institute (NHLBI), part of ... totaling $23.6 million to begin preclinical testing of devices ... those who develop heart failure. The four-year program is ... Each year in the United States, nearly 1,800 infants ...
... ... its Cryopak subsidiary in Maromme, France. Officially starting operations in March of 2009, Cryopak, ... scale to companies across Europe. , ... Edison, NJ (PRWEB) February 4, 2010 -- www.cryopak-europe.com-- TCP Reliable has ...
Cached Medicine News:Health News:HeartMath Offers Free Certificates that Celebrate Love and the Heart 2Health News:HeartMath Offers Free Certificates that Celebrate Love and the Heart 3Health News:Texas Health Dallas Launches Screening Program for Female Heart Disease 2Health News:Texas Health Dallas Launches Screening Program for Female Heart Disease 3Health News:Octapharma Accepting Applications for Research Grants Through March 31 2Health News:Octapharma Accepting Applications for Research Grants Through March 31 3Health News:Octapharma Accepting Applications for Research Grants Through March 31 4Health News:Melatonin precursor stimulates growth factor circuits in brain 2Health News:NHLBI funds preclinical tests on devices for infants and children with congenital heart defects 2Health News:NHLBI funds preclinical tests on devices for infants and children with congenital heart defects 3Health News:Cryopak France Opening Signifies New Vision for Global Manufacturing for the Cold Chain Industry 2
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Full Service CRO WCCT ... Vice President of Business Development. Peter has been in ... number of different business development positions with some of ... primarily related to business development/sales management and marketing.  The ... makes him a key and strategic asset to WCCT ...
(Date:7/25/2014)... Tobago , July 25, 2014  The ... & Tobago Ministry of Health approved the introduction ... significantly increases the cure rate from Hepatitis C, ... the genotype 1 virus. Telaprevir is available in ... brand INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg ...
(Date:7/25/2014)... , July 25, 2014  Solanbridge Group Inc ... acquired the majority interest in Buzznbrewz.com and the Letter ... replaced with a fully executed Purchase Agreement. ... stated "We are proud to have Mr. David ... decades of experience in the private sector and developed ...
Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... Pharmaceuticals, a leading manufacturer of critical care products, celebrates ... new website. In the last four years, Novis has ... technology (RXID), customer focus, service excellence and superior compliance ... provide our customers with outstanding service. We have a ...
... TITUSVILLE, N.J., April 14, 2011 Ortho-McNeil Neurologics ... is voluntarily recalling two lots of TOPAMAX ® ... shipped between 10/19/2010 and 12/28/2010 and distributed in ... encompasses approximately 57,000 bottles of TOPAMAX ® , ...
Cached Medicine Technology:Novis Pharmaceuticals Celebrates Four Years With New Website Launch 2Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of TOPAMAX® 2Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of TOPAMAX® 3Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of TOPAMAX® 4Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of TOPAMAX® 5
1-Day Acuvue brand contact lenses offer the healthiest, most convenient way to wear contact lenses. There's no lens care or messy solutions required, just wear them one day and throw them away....
PLX40s, 40 Watt Sealed CO2 Laser System....
... The UltraPulse system's capability to quickly deliver ... one pulse allows for powerful single-pulse ablation. ... UltraPulse system the coldest and cleanest CO2 ... power is combined with the independent adjustment ...
... The NIDEK OPD-Scan II provides information ... and pupillometry in one unit, utilizing ... specifically to measure normal to highly ... variety of data maps to provide ...
Medicine Products: